Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Pharmacyclics, Inc. today announced the initiation of PCYC-1136-CA, a multi-center study that will investigate the use of ibrutinib (IMBRUVICA®) in...
Pharmacyclics, Inc. (NASDAQ: PCYC) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...
Pharmacyclics, Inc. (NASDAQ: PCYC) announced today that ibrutinib (IMBRUVICA®) single-agent and combination data will be featured in seven oral and...
Pharmacyclics, Inc. (the "Company") (NASDAQ: PCYC) today reported financial results for the quarter ended March 31, 2015, as well as general business ...
Ibrutinib (IMBRUVICA®) data presented yesterday by Pharmacyclics, Inc. (NASDAQ: PCYC) at the American Association for Cancer Research (AACR) Annual...
Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that IMBRUVICA® (ibrutinib) follow-up data in treatment-naive (TN) and relapsed/refractory (R/R)...
Pharmacyclics, Inc. (NASDAQ: PCYC) today announced longer-term data from a Phase II investigator-initiated study showing Waldenstrom's...
Pharmacyclics, Inc. (NASDAQ: PCYC) today announced the initiation of PCYC-1135-CA, a multi-center study that will investigate the use of ibrutinib...
Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that new pre-clinical and clinical data for ibrutinib (IMBRUVICA®) will be highlighted at the 2015 ...
Pharmacyclics, Inc. (NASDAQ: PCYC) announced today that an Independent Data Monitoring Committee reviewed and assessed HELIOS (CLL3001), an...
Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that longer-term toxicology studies for its newly developed Bruton's tyrosine kinase (BTK)...
Pharmacyclics, Inc. (NASDAQ: PCYC) today highlighted findings from a pre-clinical study published in the Proceedings of the National Academy of...
Pharmacyclics, Inc. (the "Company") (NASDAQ: PCYC) today reported financial results for the quarter and year ended December 31, 2014, as well as...
Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that treatment with IMBRUVICA® (ibrutinib) was associated with an 88% overall response rate (ORR), ...
Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it will hold a conference call and audio webcast to discuss its financial results for the...
Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that the U.S. Food and Drug Administration (FDA) has granted single-agent IMBRUVICA® (ibrutinib)...
Pharmacyclics, Inc. (NASDAQ: PCYC) today provided its preliminary unaudited 2014 U.S. net product revenue results and 2015 U.S. net product revenue...
Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that treatment with single-agent IMBRUVICA® (ibrutinib) in treatment-naive and previously treated...
Pharmacyclics, Inc. (NASDAQ: PCYC) announced today that the U.S Food and Drug Administration (FDA) has provided a Prescription Drug User Fee Act...
Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it has been awarded BayBio's 2014 Pantheon DiNA™ Award for Outstanding Company for its rapid...
New, 27-month IMBRUVICA® (ibrutinib) median follow-up data announced by Pharmacyclics, Inc. (NASDAQ: PCYC) today support the use of IMBRUVICA over...
New IMBRUVICA® (ibrutinib) Phase II data announced by Pharmacyclics, Inc. (NASDAQ: PCYC) today demonstrates its potential utility as a combination...
Pharmacyclics, Inc. (NASDAQ: PCYC) today announced new, longer term data in IMBRUVICA® (ibrutinib) patients with relapsed/refractory chronic...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.